Technical Information
MDMB-BUTINACA
- DMF: 20 mg/ml
- DMSO: 5 mg/ml
- Ethanol: 20 mg/ml
Cryopreserved pooled primary human hepatocyte (HHep) incubations
Hepatocyte incubation and metabolite identification experiments were performed
according to a published procedure33, 34 with slight modifications. Briefly, 5 μmol/L ADB-BUTINACA (obtained from the National Forensic Centre, Sweden) and
(S)-ADB-4en-PINACA (synthesized at Linköping University, see above) were incubated with HHeps (1 × 105 cells in 100 μl) in a total volume of 100 μl.
The synthesis and in vitro pharmacological evaluation of ADB-BUTINACA and ADB-4en-PINACA has been reported recently.20, 29-31
analysis by ultra-high pressure liquid chromatography coupled to high resolution accurate mass spectrometry (UHPLC-HRAM-MS, ADB-BUTINACA, and ADB-4en-PINACA)
| 4F-MDMB-BINACA Methyl 2-[[1-(4-fluorobutyl)indazole-3-carbonyl]amino]-3,3- dimethyl-butanoate, methyl 2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate 4F-MDMB-BUTINACA |
|
| methyl 2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate | |
| Synthetic cannabinoids | |
| Synthetic cannabinoid receptor agonists | |
|
InChI=1S/C19H26FN3O3/c1-19(2,3)16(18(25)26-4)21-17(24)15-13-9-5-6-10-14(13)23(22-15)12-8-7-11-20/h5-6,9-10,16H,7-8,11-12H2,1-4H3,(H,21,24)
|
|
|
GZGKSDAMWRWYOZ-UHFFFAOYSA-N
|
|
|
CC(C)(C)C(NC(C1=NN(CCCCF)C2=C1C=CC=C2)=O)C(OC)=O
|
|
| C19H26FN3O3 | |
| 363.4265 g/mol | |
| 71/II | |
|
This substance is included in Schedule II of the 1971 Convention on Psychotropic Substances. |
